Prescription Drug Coverage Updates for Second Quarter 2018
CVS Caremark™, NRECA’s pharmacy benefit manager, has announced changes to the Performance Drug List, which is the formulary containing the most commonly prescribed brand and generic drugs, effective April 1, 2018.
CVS Caremark continually reviews and updates the formulary to help ensure NRECA participants have access to safe, reliable and affordable prescription drugs.
These products added to the formulary have enhanced effectiveness and/or provide more convenient dosages compared to available options on the formulary:
- Estring Vaginal Ring, Fiasp, Trelegy Ellipta inhaler, Mirena, Kyleena, Skyla, Tolak Cream
These excluded products may have less convenient dosages, more side effects or a higher cost compared to other options:
- Alevicyn products
These products will move from Tier 2 to Tier 3 within the formulary, which may affect the copay or coinsurance amount.
- Brisdelle, Liletta IUD, Renvela, Erivedge, Verzenio
- Tamiflu may change tiers after April 1 (as the flu season comes to an end). CVS Caremark will be monitoring the availability of a generic alternative and may make a tier-change decision if necessary.
CVS Caremark will send a letter to participants affected by the drug exclusions the week of February 26. Participants impacted by the tier changes will receive a letter from CVS Caremark in early March.
Participants can visit the Prescription Drug page on the NRECA Employee Benefits website to view the most current version of the Performance Drug List, request mail service (for the most affordable prescriptions) and access drug prices and information.
If you or your employees have questions about prescription drug coverage or these changes, call CVS Caremark Customer Care at 888.796.7322.